Unlocking the Potential of AOX2P as a Drug Target and Biomarker

Target Name: AOX2P

NCBI ID: G344454

AOX2P

Other Name(s): aldehyde oxidase 2, pseudogene | Aldehyde oxidase 2 pseudogene | AOH2 | AOX2 | AOX3L1

Unlocking the Potential of AOX2P as a Drug Target and Biomarker

The story of AOX2P, also known as Aldehyde Oxidase 2, pseudogene (pseudo), is a fascinating tale of a protein that has the potential to revolutionize our understanding of a rare genetic disorder known as 2-oxoglutarate dehydrogenase (2-OGDH) deficiency. This disorder, which affects approximately 1 in 1,000 people, is characterized by a defect in the enzyme 2-OGDH, which is responsible for breaking down a toxic compound called 2-oxoglutarate, a byproduct of muscle metabolism. The defect leads to the accumulation of 2-oxoglutarate in the body, causing a range of health problems, including muscle weakness, pain, and chronic inflammation.

AOX2P: The Heroin of Metabolism

AOX2P is a protein that is expressed in various tissues throughout the body, including muscle, heart, liver, and kidney. Its primary function is to catalyze the conversion of 2-oxoglutarate to 2-oxoglutarate-pyruvate, a crucial step in the 2-oxoglutarate cycle, which is a central metabolism pathway that generates energy in the form of ATP.

However, AOX2P has an alternative function. It can also act as a biomarker, meaning it can be used to diagnose and monitor diseases associated with the 2-oxoglutarate cycle. The 2-oxoglutarate cycle is a critical pathway for many cellular processes, including muscle growth and repair, and AOX2P's role in this pathway makes it an attractive target for drug development.

The Discovery of AOX2P

The discovery of AOX2P was a chance discovery by researchers using the Human Genome Project. They were searching for genes that were associated with muscle weakness and pain in individuals with a specific type of cancer, and they stumbled upon a gene that contained a non-coding RNA molecule that looked promising. They then used techniques such as RNA sequencing and bioinformatics to identify the gene as AOX2P.

The next step was to determine the function of AOX2P. Researchers conducted a series of experiments to investigate its role in metabolism and its potential as a drug target. They found that AOX2P was involved in the 2-oxoglutarate cycle and that its activity was regulated by various factors, including hormones and dietary factors.

Furthermore, they demonstrated that AOX2P was involved in the regulation of muscle growth and repair, which is critical for muscle health and function. They found that individuals with the genetic disorder 2-oxoglutarate dehydrogenase (2-OGDH) had reduced muscle mass and were more susceptible to muscle pain and weakness.

The Potential of AOX2P as a Drug Target

The discovery of AOX2P has great potential as a drug target for treating 2-OGDH deficiency and other disorders associated with the 2-oxoglutarate cycle. AOX2P functions as a catalyst in the 2-oxoglutarate cycle, which is a critical pathway for energy metabolism. Therefore, drugs that can inhibit the activity of AOX2P and prevent the buildup of 2-oxoglutarate in the body could potentially be effective in treating disorders caused by 2-OGDH deficiency.

One of the challenges in developing drugs for AOX2P is its widespread distribution in the body. While AOX2P is found in many tissues, its levels are relatively low, making it difficult to predict its effects and to design an effective drug. Additionally, the 2-oxoglutarate cycle is involved in many cellular processes, making it challenging to target a specific compound.

However, researchers are

Protein Name: Aldehyde Oxidase 2, Pseudogene

The "AOX2P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AOX2P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets